Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Veronique Jestin-Le Tallec"'
Autor:
Karim Amrane, Philippe Thuillier, David Bourhis, Coline Le Meur, Chloe Quere, Jean-Christophe Leclere, Marc Ferec, Veronique Jestin-Le Tallec, Laurent Doucet, Pierre Alemany, Pierre-Yves Salaun, Jean-Philippe Metges, Ulrike Schick, Ronan Abgral
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract The main aim of this study was to evaluate the prognostic value of radiomic approach in pre-therapeutic 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET/CT) in a large cohort of patients with gastro-esophageal junction cancer (GE
Externí odkaz:
https://doaj.org/article/9c06887eb2e047218fac155ba9763e1b
Autor:
Karim Amrane, Philippe Thuillier, David Bourhis, Coline Le Meur, Chloe Quere, Jean-Christophe Leclere, Marc Ferec, Veronique Jestin-Le Tallec, Laurent Doucet, Pierre Alemany, Pierre-Yves Salaun, Jean-Philippe Metges, Ulrike Schick, Ronan Abgral
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/d2fad35265b444fba3cf77cd4083c3d4
Autor:
Veronique Jestin Le Tallec, Jean-Philippe Metges, Hélène Simon, Cedric Verveur, Fanny Trouboul, Yves Eusen, Caroline Cheneau, Jerome Martin-Babau
Publikováno v:
Journal of Clinical Oncology. 34:152-152
152 Background: Trastuzumab is widely used in Her2 positive metastatic esophageal and gastric cancers along with chemotherapy. Cardiotoxicity of trastuzumab has been described precisely in Her2 positive breast cancers and occurs with asymptomatic low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a547fb46fbe93d200ea8a76f35df079
https://doi.org/10.1200/jco.2016.34.4_suppl.152
https://doi.org/10.1200/jco.2016.34.4_suppl.152
Autor:
Jean-Philippe Metges, D. Visvikis, Pierre Teyton, Patrick Lozac'h, Catherine Cheze Le Rest, Veronique Jestin Le Tallec, A. Volant
Publikováno v:
Nuclear medicine communications. 29(7)
Objectives Esophageal cancer outcome greatly depends on the pathological stage. Our objectives were to assess prognosis on the basis of the initial fluorodeoxyglucose (FDG)-PET scan, focusing on the correlation between overall survival and FDG uptake
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02ac7a17f51bc66f19ce45c37f02fe18
https://pubmed.ncbi.nlm.nih.gov/18528185
https://pubmed.ncbi.nlm.nih.gov/18528185
Autor:
Sylvie Van Hulst, Jerome Martin-Babau, Olivier Dupuis, Roger Faroux, Laurent Miglianico, Jean-Philippe Metges, Marc Porneuf, Claire Stampfli, Veronique Jestin Le Tallec, C. El Hannani, Philippe Deguiral, James Bassoulet, Christian Riche, Jean-Yves Douillard, Fanny Marhuenda, A. Gourlaouen, Jean-Luc Raoul, Delphine Deniel Lagadec, F. Grude, Jean François Ramée
Publikováno v:
Journal of Clinical Oncology. 33:714-714
714 Background: Metastatic Colorectal Cancer (mCRC) often occurs in patients older than 70 years old. Monoclonal antibodies targeting EGFR have improved the outcome of mCRC patients. Panitumumab in monotherapy is indicated in wild-type K-RAS mCRC pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f60d0f2b0b630fbb832df805eaaa0db
https://doi.org/10.1200/jco.2015.33.3_suppl.714
https://doi.org/10.1200/jco.2015.33.3_suppl.714